CA2961607C - Mk2 inhibitors and uses thereof - Google Patents

Mk2 inhibitors and uses thereof Download PDF

Info

Publication number
CA2961607C
CA2961607C CA2961607A CA2961607A CA2961607C CA 2961607 C CA2961607 C CA 2961607C CA 2961607 A CA2961607 A CA 2961607A CA 2961607 A CA2961607 A CA 2961607A CA 2961607 C CA2961607 C CA 2961607C
Authority
CA
Canada
Prior art keywords
compound
disorder
disease
aliphatic
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2961607A
Other languages
English (en)
French (fr)
Other versions
CA2961607A1 (en
Inventor
Matthew David Alexander
Claudio Chuaqui
John MALONA
Joseph John MCDONALD
Yike Ni
Deqiang Niu
Russell C. Petter
Juswinder Singh
Chittari Pabba
Guobin MIAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Celgene CAR LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene CAR LLC filed Critical Celgene CAR LLC
Publication of CA2961607A1 publication Critical patent/CA2961607A1/en
Application granted granted Critical
Publication of CA2961607C publication Critical patent/CA2961607C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
CA2961607A 2014-09-17 2015-09-16 Mk2 inhibitors and uses thereof Active CA2961607C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462051788P 2014-09-17 2014-09-17
US62/051,788 2014-09-17
US201562199927P 2015-07-31 2015-07-31
US62/199,927 2015-07-31
PCT/US2015/050495 WO2016044463A2 (en) 2014-09-17 2015-09-16 Mk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
CA2961607A1 CA2961607A1 (en) 2016-03-24
CA2961607C true CA2961607C (en) 2023-03-28

Family

ID=55454109

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2961607A Active CA2961607C (en) 2014-09-17 2015-09-16 Mk2 inhibitors and uses thereof

Country Status (30)

Country Link
US (5) US9458175B2 (2)
EP (2) EP3912981A1 (2)
JP (3) JP6556225B2 (2)
KR (1) KR102457848B1 (2)
CN (1) CN106998692B (2)
AU (1) AU2015317741B2 (2)
BR (1) BR112017005266B1 (2)
CA (1) CA2961607C (2)
CL (1) CL2017000576A1 (2)
CO (1) CO2017003279A2 (2)
CY (1) CY1124215T1 (2)
DK (1) DK3193611T3 (2)
EA (1) EA037299B1 (2)
EC (1) ECSP17023281A (2)
ES (1) ES2874561T3 (2)
HR (1) HRP20210529T1 (2)
HU (1) HUE054347T2 (2)
IL (1) IL251051B (2)
LT (1) LT3193611T (2)
MA (1) MA40534B1 (2)
MX (2) MX373341B (2)
PL (1) PL3193611T3 (2)
PT (1) PT3193611T (2)
RS (1) RS62017B1 (2)
SA (1) SA517381115B1 (2)
SG (2) SG11201701861RA (2)
SI (1) SI3193611T1 (2)
SM (1) SMT202100311T1 (2)
TW (1) TWI744217B (2)
WO (1) WO2016044463A2 (2)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016518316A (ja) 2013-03-15 2016-06-23 セルジーン アビロミクス リサーチ， インコーポレイテッド Ｍｋ２阻害剤およびそれらの使用
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
US10882867B2 (en) * 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
US11230551B2 (en) 2017-03-16 2022-01-25 Celgene Car Llc Deuterated analogs of MK2 inhibitors and uses thereof
JP7282039B2 (ja) * 2017-03-16 2023-05-26 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤、その合成、およびそれに至るまでの中間体
WO2018170204A1 (en) * 2017-03-16 2018-09-20 Celgene Car Llc 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof
JP7200120B2 (ja) 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
CN107058259A (zh) * 2017-05-18 2017-08-18 南京中医药大学 分子标志物mk2基因及其应用
CA3114883A1 (en) 2018-10-02 2020-04-09 Disc Medicine, Inc. Matriptase 2 inhibitors and uses thereof
CN114364681A (zh) * 2019-05-17 2022-04-15 西建卡尔有限责任公司 治疗mk2介导的病症的方法
KR20220153582A (ko) 2020-02-14 2022-11-18 솔크 인스티튜트 포 바이올로지칼 스터디즈 마크로시클릭 ulk1/2 억제제
JP2023513797A (ja) * 2020-02-14 2023-04-03 ソーク インスティテュート フォー バイオロジカル スタディーズ Ｕｌｋ１／２阻害剤による単剤療法および併用療法
US20230087078A1 (en) * 2020-03-02 2023-03-23 Washington University Compositions and methods for the treatment of pancreatic cancer
US20230255979A1 (en) * 2020-07-24 2023-08-17 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders
US20230414575A1 (en) * 2020-11-12 2023-12-28 Akttyva Therapeutics, Inc. Mk2 activating compounds for use in treating vascular leak and endothelial barrier disorders
KR20230142529A (ko) * 2021-02-01 2023-10-11 셀진 코포레이션 Mk2 억제제, 이의 합성, 및 이의 중간체
EP4079855A1 (en) * 2021-04-20 2022-10-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound and method for the prophylaxis and treatment of leukemia
TW202328141A (zh) * 2021-08-27 2023-07-16 大陸商瑞石生物醫藥有限公司 喹啉并呋喃衍生物及其用途
MX2024008704A (es) 2022-01-14 2024-07-22 Shanghai Hansoh Biomedical Co Ltd Derivado policiclico que contiene piridina, y metodo de preparacion de este y uso de este.
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
EP4608401A2 (en) * 2022-10-27 2025-09-03 Bristol-Myers Squibb Company Mk2 inhibitors and uses thereof
US20260109708A1 (en) * 2023-02-07 2026-04-23 Celgene Corporation Compounds and compositions useful as degraders of mk2 kinase
WO2024229401A2 (en) * 2023-05-04 2024-11-07 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
CN121368484A (zh) * 2023-06-26 2026-01-20 深圳信立泰药业股份有限公司 一种mk2抑制剂在制备预防和/或治疗疾病药物中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CN1747949A (zh) 2002-12-20 2006-03-15 法马西亚公司 无环吡唑化合物
EP1663204B1 (en) 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
MX2007009388A (es) 2005-02-04 2007-09-25 Senomyx Inc Compuestos que comprenden porciones heteroarilo unidas y su uso como modificadores del sabor unami, saborizantes y mejoradores del sabor para composiciones comestibles.
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
CN101687869A (zh) 2007-07-16 2010-03-31 诺瓦提斯公司 作为mk2抑制剂的四环内酰胺衍生物
CN101910151A (zh) 2007-10-22 2010-12-08 先灵公司 双环杂环衍生物及其作为gpr119活性调节剂的用途
TWI546290B (zh) 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
WO2011153553A2 (en) * 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2508511A1 (en) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
ES2742261T3 (es) * 2011-04-15 2020-02-13 Hivih Inhibidores de la replicación viral, su proceso de preparación y sus usos terapéuticos
KR102251706B1 (ko) 2012-02-22 2021-05-14 메르크 파텐트 게엠베하 액정 매질
EP2832734A4 (en) * 2012-03-28 2015-08-26 Takeda Pharmaceutical HETEROCYCLIC COMPOUND
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
HK1210696A1 (en) * 2012-07-11 2016-05-06 Nimbus Iris, Inc. Irak inhibitors and uses thereof
BR112015006418A2 (pt) * 2012-09-24 2017-07-04 Speede Claremont método para apagar dados iniciados por um dispositivo de usuário de remetente remoto; e sistema de armazenamento de entrega de dados entre um dispositivo de usuário remetente e um dispositivo de usuário de destino
TW201417817A (zh) * 2012-09-25 2014-05-16 Daiichi Sankyo Co Ltd Ｇｓｋ３抑制劑與抗ｄｒ５抗體之組合
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
JP2016518316A (ja) * 2013-03-15 2016-06-23 セルジーン アビロミクス リサーチ， インコーポレイテッド Ｍｋ２阻害剤およびそれらの使用
WO2015050957A2 (en) 2013-10-02 2015-04-09 Treatments For Systemic Lupus Erythematosus Treatments for systemic lupus erythematosus
WO2016032882A1 (en) 2014-08-25 2016-03-03 Stc.Unm Inhibition of mk2 in the treatment of cancer
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
WO2016112292A1 (en) 2015-01-08 2016-07-14 Moerae Matrix, Inc. Formulation of mk2 inhibitor peptides
WO2018170204A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
US11230551B2 (en) 2017-03-16 2022-01-25 Celgene Car Llc Deuterated analogs of MK2 inhibitors and uses thereof
JP7282039B2 (ja) 2017-03-16 2023-05-26 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤、その合成、およびそれに至るまでの中間体
JP7200120B2 (ja) 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
CN114364681A (zh) 2019-05-17 2022-04-15 西建卡尔有限责任公司 治疗mk2介导的病症的方法
US20230255979A1 (en) 2020-07-24 2023-08-17 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders

Also Published As

Publication number Publication date
SMT202100311T1 (it) 2021-07-12
US20210053984A1 (en) 2021-02-25
PL3193611T3 (pl) 2021-10-04
JP6556225B2 (ja) 2019-08-07
JP7375072B2 (ja) 2023-11-07
ECSP17023281A (es) 2017-06-30
AU2015317741A1 (en) 2017-04-20
EP3193611A4 (en) 2018-02-28
DK3193611T3 (da) 2021-05-10
EA037299B1 (ru) 2021-03-05
KR20170063734A (ko) 2017-06-08
BR112017005266B1 (pt) 2022-11-01
EP3193611B1 (en) 2021-03-24
LT3193611T (lt) 2021-08-25
CN106998692B (zh) 2020-09-08
SG11201701861RA (en) 2017-04-27
US9790235B2 (en) 2017-10-17
CY1124215T1 (el) 2022-05-27
EP3912981A1 (en) 2021-11-24
CN106998692A (zh) 2017-08-01
AU2015317741B2 (en) 2020-01-16
CO2017003279A2 (es) 2017-09-29
PT3193611T (pt) 2021-05-28
US20170114073A1 (en) 2017-04-27
US10253040B1 (en) 2019-04-09
JP2017529367A (ja) 2017-10-05
MX373341B (es) 2020-05-26
MX2017003359A (es) 2017-11-22
SA517381115B1 (ar) 2021-03-09
US10577380B2 (en) 2020-03-03
BR112017005266A2 (pt) 2017-12-12
TWI744217B (zh) 2021-11-01
CA2961607A1 (en) 2016-03-24
RS62017B1 (sr) 2021-07-30
CL2017000576A1 (es) 2017-12-01
MA40534B1 (fr) 2021-04-30
WO2016044463A3 (en) 2016-09-01
EA201790380A1 (ru) 2017-08-31
EP3193611A2 (en) 2017-07-26
JP2019194236A (ja) 2019-11-07
WO2016044463A2 (en) 2016-03-24
MX2020005213A (es) 2020-08-20
ES2874561T3 (es) 2021-11-05
HRP20210529T1 (hr) 2021-08-06
US9458175B2 (en) 2016-10-04
IL251051A0 (en) 2017-04-30
KR102457848B1 (ko) 2022-10-25
US20190375762A1 (en) 2019-12-12
NZ730603A (en) 2024-02-23
SG10201902326XA (en) 2019-04-29
TW201617351A (zh) 2016-05-16
JP2022078315A (ja) 2022-05-24
HUE054347T2 (hu) 2021-08-30
SI3193611T1 (sl) 2021-08-31
US11584757B2 (en) 2023-02-21
US20160075720A1 (en) 2016-03-17
MA40534A (fr) 2016-03-24
IL251051B (en) 2019-11-28

Similar Documents

Publication Publication Date Title
CA2961607C (en) Mk2 inhibitors and uses thereof
EP3080103B9 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
CN112638910B (zh) 新的杂环胺衍生物及包含其的药物组合物
WO2016090079A1 (en) Heteroaryl compounds and uses thereof
EP4209485A1 (en) Compound having antitumor activity and use thereof
KR20210108433A (ko) 티에노피리디논 화합물
HK1241225B (en) Mk2 inhibitors and uses thereof
HK1241225A1 (en) Mk2 inhibitors and uses thereof
CN120676947A (zh) 可用作mk2激酶降解剂的化合物和组合物
EP4608401A2 (en) Mk2 inhibitors and uses thereof
HK40058075A (en) Intermediates and processes for the preparation of biaryl compounds
HK1229333B (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
HK1229333A1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200828